EHMT2 and acute lymphoblastic leukemia: To validate G9a as a therapeutic target in T-ALL, we intersected our results with a previously published short hairpin RNA (shRNA) screen targeting nearly 350 chromatin regulator genes in DND41 T-ALL cell line [19].